Calvin Lam
Lawyers
Filters
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Zhejiang Expressway $860 million rights issue
The H shares are listed on the Hong Kong Stock Exchange
MedSci Healthcare Holdings HK$608 million IPO
We advised MedSci on its IPO and HKEX listing
ZJLD Group HK$5.3 billion IPO
We advised ZJLD on its IPO and HKEX listing
Bilibili convertible notes exchange and concurrent follow-on equity offering
The transaction involved a convertible notes exchange and a concurrent follow-on offering of ADSs
Tuya global offering and dual primary listing on the Hong Kong Stock Exchange
We advised Tuya Inc. on its HK$141 million global offering and dual primary listing on the HKEX